| OHDSI Home | Forums | Wiki | Github |
In a large observational database (e.g., Medicare), there may be a large number of patients on Hydroxychloroquine. Some of them (due to various reasons) may be also exposed to Azithromycin.
Hydroxychloroquine by itself prolongs the QT interval. The FDA CDER director tweeted about increased risk when hydroxychloroquine is combined with Azithromycin.
Can someone comment on study design that would be best to use to investigate this using OHDSI packages? @schuemie @msuchard @edburn
Thanks @Vojtech_Huser, this is specifically in scope of the study that @Daniel_Prieto and the team are leading on the safety of hydroxychloroquine that we initiated during the Covid-19 study-a-thon, which we are trying to wrap up this week. I think our community will have something meaningful to contribute to this discussion.
Results of a trial on this question
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial
trial registration record
https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-000890-25/FR
This is the study which contributed to all the controversy and has been criticised by many…Prof Gautret is being treated like a rock star in France.
